“

Research projects will explore the role of the tyrosine kinase inhibitor neratinib in different tumor types.

“

New executive will lead the National Comprehensive Cancer Network's programs for sharing evidence- and expert consensus-based resources to improve cancer care.

doi: 10.6004/jnccn.2020.0061

NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers

The NCCN Oncology Research Program (ORP) announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of EGFR and HER2. The research funding is supported by a \$2 million grant from Puma Biotechnology, Inc.

Projects may include preclinical, translational, and clinical trials. They will focus on treatment of:

- Pediatric tumors (including neurofibromatosis type 2 and progressive vestibular schwannoma),
- Early-stage and metastatic breast cancer, including those with HER2+ brain metastases,
- Other HER2-amplified tumors, and
- EGFR-mutated glioblastoma multiforme.

Specific research areas will be determined by a group of cancer research experts from NCCN Member Institutions who form a Request for Proposals (RFP) Development Team.

"We look forward to advancing knowledge of the role this dual-HER breast cancer drug may have in improving outcomes for various cancer presentations," said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. "The projects we oversee will provide important information on this emerging mechanism for personalized cancer care."

"We thank the National Comprehensive Cancer Network for their inclusion of neratinib for further evaluation," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We are proud to support NCCN's research projects to better understand the full potential of neratinib across a variety of indications. Our goal is to use these insights to expand the potential indications, as well as to identify patients who may benefit from neratinib."

The first phase of this project will involve the creation of an RFP, which will open in early 2021. The awarded projects will be announced following review of submitted proposals.

The NCCN ORP fosters innovation and knowledge discovery that improves the lives of people with cancer and supports preclinical, translational, and clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website and an informed consent database. For more information, visit NCCN.org/orp.

NCCN Announces Beth Gaffney, MBA, as New Vice President of U.S. and Global Business Development

NCCN is pleased to announce the addition of Beth Gaffney, MBA, as the new Vice President of U.S. and Global Business Development. In this role, Gaffney oversees both U.S. and global business activities and the development of the NCCN brand worldwide. She will work closely with other members of the NCCN senior leadership team to ensure the influence of NCCN content and the ongoing

Cont. on page xxxii.

Cont. from page xxx.

collaboration, and support of all of our stakeholders. Gaffney will lead multiple functional areas across the organization, including business development (U.S. and global), business insights, commercial licensing, health information technology, and payer and employer outreach. She will also work in conjunction with NCCN's marketing and communications department and oncology policy program.

Gaffney is a graduate of The Wharton School of the University of Pennsylvania with more than 15 years of strategic business development and marketing experience in the healthcare industry, most recently serving as head of business development for risk management and patient support services for United Biosource Corporation. Prior to that she held positions with Johnson & Johnson's McNeil Consumer Healthcare division and Men's Health Magazine.

"We couldn't be happier about having Beth join us for this critical business development role," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "Beth's strong leadership and biotech knowledge, combined with a lifelong passion for helping people achieve better health, make her an excellent fit as our new Vice President of U.S. and Global Business Development. She will be a leading voice for our important collaborations across the oncology ecosystem worldwide."

"I am thrilled to have the opportunity to join NCCN," said Gaffney. "To be a part of the NCCN team dedicated to improving cancer care so that patients can live better lives is truly an honor. I look forward to leading Business Development and joining the effort to further advance NCCN's mission globally."

Gaffney joined NCCN on October 27, 2020.